Upon loco-regional relapse, he received standard therapy first with doublet immunotherapy [2], which was stopped due to autoimmune toxicity, and then, given a B-raf mutation in his melanoma, doublet oral targeted therapy [3] from which he has had a sustained response. The gene discussed is BRAF; the disease is melanoma.